Olivares-Guzmán LO, Escobar-Ceballos LGS, Gómez-Castaños PC, Coss-Adame E, Furusho-Yamamoto JK, Sarmiento-Aguilar A

Language: Spanish
References: 12
Page: 71-75
PDF size: 560.48 Kb.

ABSTRACT

Introduction. Small intestinal bacterial overgrowth (SIBO) is present in different gastrointestinal diseases, especially in the presence of predisposing conditions. It is difficult to define the true prevalence of SIBO in patients with ulcerative colitis (UC) because of the variety of clinical manifestations that patients with SIBO present, which can be similar to other conditions. There are no previous studies regarding SIBO in Mexican patients with UC. Thus, the goal of this study was to evaluate the frequency of SIBO by means of breath tests in patients with active and remission UC compared to non-UC controls.
Material and methods. Cross-sectional study in patients with histopathological diagnosis of UC in clinical, biochemical and endoscopic remission (Mayo 0-1) who met the criteria to undergo a hydrogen and methane breath test. The demographic and clinical variables of the patients were collected. Statistical analysis was performed with SPSS software version 24.
Results. We studied 30 patients with UC in remission with current mean age 42.5 years with a median of 5 years of evolution (range 3-9.5). Of these, 23 were women (62.2%) and 14 men (37.8%). When the breath test with hydrogen and methane was performed, the frequency of SIBO was found to be 50% (15 out of 30 patients). The orocecal transit had a median of 120 microparticles per million. The frequency of methanogenesis was universal in the course of the test with a baseline of 76.6%. None of the patients had diagnostic methane levels to confirm SIBO. There was a significant correlation between symptoms and gas increase in patients with SIBO (p = 0.006).
Conclusion. The frequency of SIBO was 50% in patients with UC in endoscopic remission, which is higher than that reported in other gastrointestinal diseases. Methanogenesis was observed in all patients. It is important to consider SIBO as a cause of gastrointestinal symptoms in patients with UC in clinical remission.

REFERENCES

1. Harbord M, Annese V, Vavricka SR. The first european evidence-based consensus on extraintestinal manifestations in inflammatory bowel disease. J Crohn's Colitis. 2016;10(3):239- 254.

2. Michele Di Stefano, Gabrielli M, Angelo GD, Rienzo TDI, Scarpellini E, Ojetti V. et al. The Diagnosis of small intestinal bacterial overgrowth: Two Steps forward, one step backwards?. Neurogastroenterol and motility. (2018);30:e13494. 4. Sachdev AH, Pimentel M. Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance. Ther Adv Chronic Dis. 2013;4(5):223-231.

3. S.V. Rana, Scarpellini E, Abenavoli L, Balsano C, Gabrielli M, Luzza F, et al. Small Intestinal Bacterial Overgrowth and Orocecal Transit Time in Patients of Inflammatory Bowel Disease. Dig Dis Sci (2013) 58:2594–2598.

4. Gabrielli M, Angelo GD, Rienzo TDI, Scarpellini E, Ojetti V. Diagnosis of small intestinal bacterial overgrowth in the clinical practice. 2013;17(Suppl 2):30-35.

5. Rezaie A, Buresi M, Lembo A, Lin H, McCallum R, Rao S, et al. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. Am J Gastroenterol. 2017 May;112(5):775-84.

6. Greco A, Caviglia GP, Brignolo P. Glucose breath test and Crohn's disease: Diagnosis of small intestinal bacterial overgrowth and evaluation of therapeutic response. Scand J Gastroenterol. 2015;50(11):1376- 1381.

7. Gasbarrini A, Lauritano EC, Gabrielli M. Small intestinal bacterial overgrowth: Diagnosis and treatment. Dig Dis. 2007;25(3):237-240.

8. Johnston KL, Brechmann T, Sperlbaum A, Schmiegel W. Small intestinal bacterial overgrowth. Vet Clin North Am Anim Pract. 2014;29(2):523-550.

9. 10.Greco A, Caviglia GP, Brignolo P. Glucose breath test and Crohn's disease: Diagnosis of small intestinal bacterial overgrowth and evaluation of therapeutic response. Scand J Gastroenterol. 2015;50(11):1376-1381.

10. 11.Bohm M, Siwiec RM, Wo JM. Diagnosis and manag ement of small intestinal bacterial overgrowth. Nutr Clin Pract. 2013;28(3):289-299. 12.Rana SV, Sharma T., Kaur J. Relationship of cytokines, oxidative stress and GI motility with bacterial overgrowth in ulcerative colitis patients. J Crohn's Colitis. 2014;8(8):859-865.

11. Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther. 2017;45(5):604-616.

12. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. J Gastroenterol. 2000 Dec;95(12):3503-6.